Paper986302
The value of adriamycin in overcoming resistance to methotrexate in tissue culture.
Hill BT and 2 others. Eur J Cancer (1965), 1976. Cited by 51 papers, by iCite.
Cite this record
ConductScience Library. The value of adriamycin in overcoming resistance to methotrexate in tissue culture. Papers, record 986302. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/986302
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Doxorubicin | Major topic |
| Leukemia, Experimental | Major topic |
| Methotrexate | Major topic |
| Animals | |
| Cell Survival | |
| Cells, Cultured | |
| Clone Cells | |
| Dinitrophenols | |
| Dose-Response Relationship, Drug | |
| Drug Resistance | |
| Leukemia L1210 | |
| Temperature |
Source PubMed
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 51 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 7105380 | Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7105380 | PubMed |
| 4006047 | Cross resistance to esters of methotrexate in a doxorubicin-resistant subline of P388 murine leukemia. | Cancer Chemother Pharmacol | 1985 | https://conductscience.org/library/papers/4006047 | PubMed |
| 3858013 | Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro. | Cancer Chemother Pharmacol | 1985 | https://conductscience.org/library/papers/3858013 | PubMed |
| 3621454 | Selective interactions of verapamil with anthraquinones in adriamycin-sensitive and -resistant murine and human tumour cell lines in vitro. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3621454 | PubMed |
| 3583643 | Spirogermanium--a novel antitumour agent expressing a lack of cross-resistance in vitro with a range of 'standard' antitumour drugs. | Invest New Drugs | 1986 | https://conductscience.org/library/papers/3583643 | PubMed |
| 3396151 | Comparative in vitro cytotoxicities of adriamycin (ADM) and 4'[(9-acridinyl)-amino] methane sulphon-m-anisidide (mAMSA) | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3396151 | PubMed |
| 2924371 | Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumour cell lines in vitro. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2924371 | PubMed |
| 291443 | [Multidrug chemotherapy of osteogenic sarcoma (author's transl)]. | Blut | 1979 | https://conductscience.org/library/papers/291443 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/986302
GET https://conductscience.org/api/papers/v1/986302/authors